Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariana Castells

Showing results (161-170 of 176) with videos related to

Pageof 18
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|May 27, 2022
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM ConsortiumPeter Valent, Karin Hartmann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2022
Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic MastocytosisJason Gotlib, Juliana Schwaab, William Shomali, et al.
Journal of the American Academy of Dermatology|February 14, 2026
Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER studyFrank Siebenhaar, Sigurd Broesby-Olsen, Mariana Castells, et al.
The Journal of Allergy and Clinical Immunology|August 14, 2021
Anaphylaxis knowledge gaps and future research priorities: A consensus reportTimothy E Dribin, David Schnadower, Julie Wang, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 8, 2021
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)Patrizia Bonadonna, Knut Brockow, Marek Niedoszytko, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2024
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024Jason Gotlib, Aaron T Gerds, Peter Abdelmessieh, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 24, 2021
Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical ReviewTheo Gülen, Cem Akin, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology|April 15, 2026
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 yearsCem Akin, Vito Sabato, Jason Gotlib, et al.
Hemasphere|December 13, 2021
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus ProposalPeter Valent, Cem Akin, Karin Hartmann, et al.
Journal for Immunotherapy of Cancer|April 10, 2024
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapySteven T Chen, Yevgeniy R Semenov, Allireza Alloo, et al.
Pageof 18

Showing results (161-170 of 176) with videos related to

Sort By:
Pageof 18
The Journal of Allergy and Clinical Immunology. in Practice|May 27, 2022
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM ConsortiumPeter Valent, Karin Hartmann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2022
Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic MastocytosisJason Gotlib, Juliana Schwaab, William Shomali, et al.
Journal of the American Academy of Dermatology|February 14, 2026
Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER studyFrank Siebenhaar, Sigurd Broesby-Olsen, Mariana Castells, et al.
The Journal of Allergy and Clinical Immunology|August 14, 2021
Anaphylaxis knowledge gaps and future research priorities: A consensus reportTimothy E Dribin, David Schnadower, Julie Wang, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 8, 2021
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)Patrizia Bonadonna, Knut Brockow, Marek Niedoszytko, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2024
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024Jason Gotlib, Aaron T Gerds, Peter Abdelmessieh, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 24, 2021
Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical ReviewTheo Gülen, Cem Akin, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology|April 15, 2026
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 yearsCem Akin, Vito Sabato, Jason Gotlib, et al.
Hemasphere|December 13, 2021
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus ProposalPeter Valent, Cem Akin, Karin Hartmann, et al.
Journal for Immunotherapy of Cancer|April 10, 2024
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapySteven T Chen, Yevgeniy R Semenov, Allireza Alloo, et al.
Pageof 18